We were glad to take part in BioHK2026 at the Hong Kong Convention and Exhibition Centre last week, and to meet many friends and professionals from the biotech, healthcare and life sciences sectors.

Our Yolanda Wang moderated the Patent Session panel, "Protect & Resolve: The Biotech IP Playbook for Going Global," on September 12. The discussion covered practical points for biotech companies expanding internationally, including IP planning, risk management and dispute resolution.

Many thanks to the organizers, fellow panelists and everyone who joined the discussion. It was a pleasure to be part of the programme.

As biotech companies continue to look beyond their home markets, early and practical IP strategy will remain an important part of business growth.

Our Past Events

Recommended Insights

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2 December 2022
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed

14 August 2026
A Case Study of the "Electronic Blackboard" Case, (2025) SPC Zhi Xing Zhong No. 286 I. Introduction In assessing inventive step for invention patents, determining whether a technical solution would have been “readily conceivable” to a person skilled in the art has long been one of the most disputed and uncertain aspects of the analysis. […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

30 April 2021
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
Top crossarrow-right